|

Cisplatin Clinical Trials

250 actively recruiting trials across 53 locations

▼ -5 trials since June 2026

Also known as: Abiplatin, Background Platinum-based Chemotherapy, Blastolem, Briplatin, CACP +76 more

Pipeline

Early 1: 2Phase 1: 25Phase 2: 107Phase 3: 67Phase 4: 1Phase 1/2: 19Phase 2/3: 17

Top Sponsors

National Cancer Institute (NCI)21
Sun Yat-sen University12
AstraZeneca11
Merck Sharp & Dohme LLC6
M.D. Anderson Cancer Center6

Indications

Cancer250
Lung Cancer58
Non Small Cell Lung Cancer17
Cervical Cancer12
Nasopharyngeal Carcinoma10

Other116 trials

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

Phase 1/2

A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer

Phase 1

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy

Phase 2

A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies

Phase 1

A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

Phase 3

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

Phase 3

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Phase 2

A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)

Phase 2

A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.

Phase 3

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Phase 3

A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

N/A

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Phase 1/2

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Phase 1

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Phase 3

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Phase 3

A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01

Phase 1

A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's

Phase 2/3

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Phase 1/2

AB122 Platform Study

Phase 1

Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Phase 2

Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer

N/A

Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

Phase 2/3

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Phase 2

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Phase 3

Chemoradiotherapy in Unresectable Esophageal Cancer

Phase 1/2

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Phase 2/3

Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency

Phase 2/3

Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer

Phase 2

Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma

Phase 3

Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma

Phase 3

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

N/A

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Phase 2

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase 2

EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC

Phase 2

Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer

N/A

Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition

Phase 3

Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC

Phase 2

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Phase 3

Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer

Phase 3

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Phase 2

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

Phase 2

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer

Phase 2

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Phase 3

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

Phase 2

HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)

Phase 3

Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma

Phase 2

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Phase 3

Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda

Phase 2

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Phase 2

Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

Phase 2

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 3

Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread

Phase 3

Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)

Phase 3

Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

Phase 2

Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer

Phase 2

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

Phase 2

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

Phase 2

LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC

Phase 2

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Phase 2

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

Phase 3

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

Phase 3

Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma

Phase 2

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Phase 2/3

Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Phase 2/3

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Phase 2

Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma

Phase 2

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Phase 2

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Phase 2

Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

Phase 2

Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial

Phase 2

Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)

Phase 3

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

Phase 2

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

Phase 2

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

Phase 2

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

Phase 2

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Phase 3

PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

Phase 2

PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer

N/A

Pantoprazole in Cisplatin Nephrotoxicity

Phase 3

Pathological Response After Neoadjuvant Treatment on NSCLC

Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)

Phase 2

Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)

Phase 3

Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Phase 2

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

Phase 2

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Phase 3

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

Phase 2

Personalized Medicine for Advanced Biliary Cancer Patients

Phase 3

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Phase 3

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

Phase 2

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Early 1

Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study

N/A

Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial

Phase 3

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Phase 3

Radiation Therapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia in Advanced Cervical Cancer

N/A

Radiotherapy Alone Versus Concurrent Chemo-radiotherapy for Nasopharyngeal Carcincoma Patients With Undectable EBV DNA After One Cylce Neoadjuvant Chemotherpy

Phase 3

Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC

Phase 3

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Phase 2

SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Phase 2/3

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Phase 2

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

Phase 2

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

Phase 3

Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

Phase 1/2

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Phase 2

Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma

N/A

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma

Phase 2

TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

Phase 3

TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors

Phase 3

Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

Phase 2

The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma

N/A

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Phase 3

Using ctDNA to Determine Therapies for Lung Cancer

Phase 2

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Phase 2

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Phase 2

Birmingham, Alabama15 trials

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Central Alabama Research ( Site 0108)

Phase 3

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Children's Hospital of Alabama

Phase 2

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0347

Phase 3

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

University of Alabama at Birmingham

Phase 1

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Children's Hospital of Alabama

Phase 3

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Children's Hospital of Alabama

Phase 2/3

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Children's Hospital of Alabama

Phase 3

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Children's Hospital of Alabama

Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

University of Alabama at Birmingham Cancer Center

Phase 2

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

University of Alabama at Birmingham Cancer Center

Phase 2/3

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

University of Alabama at Birmingham Cancer Center

Phase 2

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Hospital of Alabama

Phase 3

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Duarte, California8 trials

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

City of Hope National Medical Center

Phase 1/2

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

City of Hope

Phase 3

A Study of ASP3082 in Adults With Advanced Solid Tumors

City of Hope National Medical Center

Phase 1

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

City of Hope(City of Hope National Medical Center, City of Hope Medical Center)

Phase 3

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

City of Hope

Phase 3

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

City of Hope Medical Center

Phase 1

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Research Site

Phase 1

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1

Los Angeles, California7 trials

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

UCLA ( Site 0317)

Phase 1/2

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

START Los Angeles, LLC

Phase 1/2

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 1/2

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)

Los Angeles County-USC Medical Center

Phase 3

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site

Phase 2

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Research Site

Phase 2

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Los Angeles General Medical Center

Phase 1/2

Houston, Texas6 trials

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

M D Anderson Cancer Center

Phase 2

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

MD Anderson Cancer Center

Phase 1/2

FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

MD Anderson Cancer Centre

N/A

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

M D Anderson Cancer Center

Phase 2

Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery

M D Anderson Cancer Center

Phase 1

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

M D Anderson Cancer Center

Phase 1

Anchorage, Alaska5 trials

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Research Site

Phase 3

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Alaska Oncology and Hematology

Phase 3

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Alaska Oncology and Hematology

Phase 1

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Alaska Oncology and Hematology

Phase 2/3

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Anchorage Associates in Radiation Medicine

Phase 3

Gilbert, Arizona5 trials

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Banner MD Anderson Cancer Center ( Site 0181)

Phase 3

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Banner MD Anderson Cancer Center

Phase 1

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Local Institution - 0167

Phase 2/3

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Banner MD Anderson Cancer Center

Phase 1/2

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Arizona Center for Cancer Care - Gilbert

Phase 2

Tucson, Arizona4 trials

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

The University of Arizona Cancer Center

Phase 1

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

University of Arizona Cancer Center-Orange Grove Campus

Phase 2

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

The University of Arizona Cancer Center-North Campus

Phase 2

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Banner University Medical Center - Tucson

Phase 2

Bethesda, Maryland4 trials

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center

Phase 2

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

National Institutes of Health Clinical Center

Phase 1

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center

Phase 1/2

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

National Institutes of Health Clinical Center

Phase 2

Boston, Massachusetts4 trials

PDT For Induction Therapy For Head And Neck Cancer

Massachusetts General Hospital

Phase 2

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Brigham and Women's Hospital

Phase 2

Toripalimab With Chemotherapy for Sinus Cancer

Brigham and Women's Hospital

Phase 2

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Beth Israel Deaconess Medical Center

Phase 2

Basking Ridge, New Jersey4 trials

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Phase 2

A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities)

Phase 2

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities

Phase 2

Phoenix, Arizona3 trials

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site

Phase 1/2

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Cancer Center at Saint Joseph's

Phase 3

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Mayo Clinic Hospital - Phoenix /ID# 272971

Phase 1/2

Little Rock, Arkansas3 trials

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

University of Arkansas for Medical Sciences

Phase 4

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060)

Phase 3

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site

Phase 2

Irvine, California3 trials

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building

Phase 2/3

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2

Santa Monica, California3 trials

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

UCLA

Phase 1

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Sarcoma Oncology Center

Phase 2/3

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Research Site

Phase 2

Stanford, California3 trials

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

GSK Investigational Site

Phase 1

A Study of LY4175408 in Participants With Advanced Cancer

Stanford Medicine Cancer Center

Phase 1

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Stanford University

Phase 3

Tampa, Florida3 trials

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

St. Joseph's Children's Hospital

Phase 2

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Moffitt Cancer Center

Phase 2

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Moffitt Cancer Center

Phase 1

Chicago, Illinois3 trials

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

University of Chicago (Data Collection Only)

Phase 2

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

University of Chicago Medicine Comprehensive Cancer Center

Phase 1

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

University of Chicago

Phase 2

New York, New York3 trials

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Memorial Sloan Kettering Cancer Centre

Phase 3

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Columbia University Irving Medical Center/ New York Presbyterian Hospital

Phase 2

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology

Phase 1/2

Pittsburgh, Pennsylvania3 trials

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

UPMC Hillman Cancer Center - Radiation Oncology

Phase 2

Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

UPMC Hillman Cancer Center

Phase 2

Window of Opportunity in Preserving Laryngeal Function Trial

UPMC Hillman Cancer

Phase 2

Mobile, Alabama2 trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

Research Site

Phase 3

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Local Institution - 0487

Phase 3

Chandler, Arizona2 trials

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Ironwood Cancer and Research Center

Phase 3

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Ironwood Cancer and Research Centers - Chandler II /ID# 275443

Phase 2/3

Scottsdale, Arizona2 trials

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Mayo Clinic in Arizona

Phase 2

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Research Site

Phase 3

Fayetteville, Arkansas2 trials

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Research Site

Phase 3

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Highlands Oncology Group - Fayetteville

Phase 2

Orange, California2 trials

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

D3 Bio Investigative Site 0402

Phase 1/2

Groningen International Study on Sentinel Nodes in Vulvar Cancer-III

UC Irvine Health/Chao Family Comprehensive Cancer Center

Phase 2

Baltimore, Maryland2 trials

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

Maryland Proton Treatment Center

Phase 1

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

SKCCC Johns Hopkins

Phase 2

Ann Arbor, Michigan2 trials

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

University of Michigan Comprehensive Cancer Center

Phase 3

Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial

University of Michigan Comprehensive Cancer Center

Phase 2

Rochester, Minnesota2 trials

Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis

Mayo Clinic in Rochester

Phase 2

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Mayo Clinic in Rochester

Phase 2

St Louis, Missouri2 trials

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Washington University School of Medicine

Phase 1

The Minimalist Trial-2

Washington University School of Medicine

Phase 2

Columbus, Ohio2 trials

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Ohio State University Comprehensive Cancer Center

Phase 2

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Ohio State University Comprehensive Cancer Center

Early 1

Philadelphia, Pennsylvania2 trials

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

Fox Chase Cancer Center

Phase 2

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Abramson Cancer Center of the University of Pennsylvania

Phase 1

Daphne, Alabama1 trial

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Southern Cancer Center (SCC) ( Site 8004)

Phase 2

Huntsville, Alabama1 trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Clearview Cancer Institute

Phase 3

Kingman, Arizona1 trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Kingman Regional Medical Center

Phase 2/3

Fort Smith, Arkansas1 trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Mercy Hospital Fort Smith

Phase 3

Beverly Hills, California1 trial

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

Cedars-Sinai Cancer at Beverly Hills (THO)

Phase 2

Buena Park, California1 trial

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Keck Medicine of USC Buena Park

Phase 2

Dublin, California1 trial

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Kaiser Permanente Dublin

Phase 2

Fullerton, California1 trial

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Research Site

Phase 2/3

La Jolla, California1 trial

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Moores Cancer Center /ID# 267782

Phase 2/3

Newport Beach, California1 trial

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Patty & George Hoag Cancer Center

Phase 3

Palo Alto, California1 trial

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Lucille Packard Children's Hospital Stanford

Phase 2

Santa Barbara, California1 trial

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Samsun Clinic - Ridley-Tree Cancer Center

Phase 3

New Haven, Connecticut1 trial

Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

Yale Cancer Center

Phase 2

Washington D.C., District of Columbia1 trial

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Johns Hopkins University: Sibley Memorial Hospital

Phase 2

Gainesville, Florida1 trial

Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma

University of Florida

Phase 2

Miami, Florida1 trial

Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

University of Miami

Phase 2

Miami Beach, Florida1 trial

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Mount Sinai Comprehensive Cancer Center ( Site 5043)

Phase 3

Atlanta, Georgia1 trial

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Emory University Hospital/Winship Cancer Institute

Phase 2

Lexington, Kentucky1 trial

Hypofractionated Radiochemotherapy

Markey Cancer Center

Phase 2

Mankato, Minnesota1 trial

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic Health Systems-Mankato

Phase 2

Buffalo, New York1 trial

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Roswell Park Cancer Institute

Phase 1/2

Cincinnati, Ohio1 trial

Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

University of Cincinnati Medical Center

Phase 2

Seattle, Washington1 trial

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.